Source: Annual Congress 2002 - Lung disposition clinical outcomes: effect of delivery device
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Weuthen, S. Häußermann, T. Meyer, J. Brauburger, G. Scheuch (Gauting, Nürnberg, Germany). Deposition of Foradil P in the human lungs- comparison of in-vitro data and in-vivo data. Eur Respir J 2002; 20: Suppl. 38, 3133

Member's Comments

No comment yet.

Related content which might interest you: Comparison of aerosol deposition pattern in healthy subjects: 3D SPECT measurements vs simulation results Source: Annual Congress 2012 - Standard of care, incidential findings, image acquisition Year: 2012 In-vitro deposition study of a levofloxacin (LEV) solution into a novel human nasal cast model by the PARI VibrENTÔ Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 The influence of inhalation flow and aerosol size on deposition: modelled vs. clinical data Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Comparison of the acceptability of dry powder inhalers. A meta-analysis based on international data Source: Eur Respir J 2002; 20: Suppl. 38, 502s Year: 2002 Automated volumetric quantification of lung emphysema: comparative analysis of different software products results. Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Correlation between inflammatory response and particulate metter in human lung. Preliminary data Source: Annual Congress 2010 - Outdoor air pollution Year: 2010 Are the spacers different in terms of lung bioavailability of salbutamol? An observational comparative study Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Comparison of drug delivery from spacers using a standard in vitro and an ex vivo method Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 A human-like ex vivo preclinical model for aerosol deposition studies Source: International Congress 2015 – New models for treating airway diseases Year: 2015 In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Do higher quantitative interferon gamma release assay or tuberculin skin test results help to predict incident tuberculosis? Data from the UK PREDICT study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 Population pharmacokinetic analysis of fluticasone propionate data from adult and pediatric subjects with asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study Source: International Congress 2017 – COPD management Year: 2017 In-vitro and in-vivo validation of Cosmed Q-box system Source: Virtual Congress 2020 – Lung function diagnostics Year: 2020 A data management and analysis platform for RASP-UK multiomics clinical datasets Source: Virtual Congress 2021 – Exacerbations of chronic respiratory diseases, including SARS-CoV-2 Year: 2021 Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses Source: Eur Respir J, 50 (1) 1700061; 10.1183/13993003.00061-2017 Year: 2017 Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001 Assessment of pulmonary drug delivery in ex vivo mouse lungs using quantitative 3D fluorescence imaging Source: International Congress 2014 – From lung imaging research to clinical use Year: 2014 Efficacy of CPAP obtained by means of automatic and mathematical titration (exploratory data) Source: Eur Respir J 2003; 22: Suppl. 45, 93s Year: 2003 Development of in-vitro models for aerosolized surfactant therapy to support customization of a novel nebulizer system based on eflow technology Source: Annual Congress 2009 - Respiratory disorders of the newborn Year: 2009